Faulkner RL, Jang MH, Liu XB, Duan X, Sailor KA, Kim JY, et al
Coverage may be available for eligible patients prescribed Wegovy, Zepbound, Ozempic, Mounjaro, semaglutide, or tirzepatide
We continue to view rising GLP-1 usage as a significant factor in the acceleration of fresh meat and produces growth rate around the perimeter of the store and stagnation in the center store and frozen aisles, the report said.
Patients who tend to do well with this program typically: Have tried diet and exercise without lasting success Are in generally good overall health Do not have a history of pancreatitis, type 1 diabetes, or certain liver or kidney conditions Want structured, clinically guided support rather than a self-managed approach Are prepared for ongoing follow-up rather than a one-time treatment If you're unsure whether you qualify, that's exactly what the consultation is for, not every patient is a fit for GLP-1 therapy, and an honest evaluation upfront is part of responsible care